 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth,insufflation, vaporization, IV |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C14H19NO2 |
| Molar mass | 233.311 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
4'-Methoxy-α-pyrrolidinopropiophenone (MOPPP) is astimulantdesigner drug of thepyrrolidinophenone class. It has the potential to produceeuphoria,[citation needed] an effect shared with other classical stimulants.
MOPPP use is infrequent when compared to otheramphetamines orstimulants used recreationally, such asmeth,cocaine, orspeed. It first arose as adesigner drug in Germany in the late 1990s and early 2000s,[1][2][3] along with a number of other derivatives but never gained the international popularity[4][5] that other drugs in its family ofpyrrolidinophenone derivatives had (such asα-PPP andMDPV).
While the recent trend of selling stimulants through false labeling (i.e.,bath salts) has gained notoriety, usingMDPV as its main ingredient, this has not been the case with MOPPP, despite its similar potential for abuse.[6]
MOPPP is structurally related toα-PPP in the same way thatPMA is related toamphetamine: amethoxy group has been added to the 4-position on thephenyl ring.
MOPPP appears to be metabolized within the liver chiefly by the enzymeCYP2D6.[2]
